This potential non-invasive way to monitor glucose metabolism in response to therapy would be particularly important for GBM EGFR inhibition, as tumor tissue-based studies have shown a high degree of heterogeneity in pharmacodynamic response15 and drug exposure in GBM.16,51. This evidence concerns the gene EGFR and glioblastoma.